INTRODUCTION
The increased detection of low-volume, early stage prostate cancer (PCa) associated to PSA screening has raised concerns regarding potential PCa overtreatment. Cryoablation and other types of focal therapy have recently received escalating attention by urologists and patients as possible strategies to avoid the morbidity associated with radical treatment. The rationale for focal therapy is to treat an organ-confined but clinically significant prostate tumor while preserving the neurovascular bundles and urinary sphincter, thus providing effective PCa control with less morbidity than radical treatment. [1] [2] [3] [4] In addition, focal therapy appears to be a good alternative between active surveillance and whole gland treatments, minimizing the risks and anxiety associated with expectant management. 4, 5 Cryoablation use has increased significantly since its establishment in 1993 6 as a minimally invasive viable treatment option for PCa, particularly in patients with early stage disease who are not candidates for prostatectomy. Cryotherapy has been used for both primary and salvage PCa treatment 7, 8 and is currently one of the primary modality for focal salvage treatment in patients who develop locally recurrent disease after external beam radiotherapy.
During the procedure, 5-12 cryo-probes are inserted percutaneously via a perineal approach under transrectal ultrasound guidance. Argon gas circulating in these probes supercools the surrounding tissue to temperatures below À 40 1C, inducing intracellular ice formation and microvascular damage, eventually leading to tissue ischemia and necrosis. 5, [9] [10] [11] [12] The most common complications of cryoablation are urethral sloughing and erectile dysfunction and damage to adjacent structures. To reduce the incidence of urethral damage, a urethral warming device consisting of a double-lumen catheter that circulates warm saline solution is currently used to maintain the urethral mucosa above freezing and preserve a thin layer of it. This approach has reduced the incidence of incontinence, urethral sloughing and irritative voiding symptoms. 12, 13 Advanced computer algorithms have made it possible to strategically plan the placement of cryo-probes in order to maximize targeted tissue destruction while sparing uninvolved adjacent structures. 14, 15 The thermal effect of the urethral warming during cryosurgery is highly dependent on the location of the cryo-probes and the protection effect is measured in a few millimeters. 16 Since the use of higher temperature in the urethral warming catheter may also 1 Pathology and Laboratory Medicine Institute, Cleveland, OH, USA; spare periurethral PCa, as tissue within certain depth beneath the urethral mucosa is not adequately treated, the distance of PCa from the urethral mucosa is an important factor to consider when contemplating cryoablation as treatment option.
The aim of our study was to evaluate preoperative parameters that could predict such distance.
MATERIALS AND METHODS
We retrospectively analyzed patients who had undergone radical prostatectomy (RP) for PCa at our institution between 2009 and 2010. Patients whose preoperative prostate biopsy (Bx) did not include the specific location of individual cores (that is, apex, mid, base) and/or received neoadjuvant therapy were excluded. Thus a total of 267 patients were included in the study. RP specimens were submitted for microscopic evaluation, as previously described. 17 All RP slides were reviewed. Outlines of all cancer foci were drawn on the slides under the microscope and then transferred onto a diagrammatic paper representation of all slices in a serial order. 17 Tumor volume at RP was calculated using the sum of the two largest tumor areas, as described previously. 18 The shortest radial distance of the nearest focus of PCa from the urethral mucosa was measured. No tissue shrinkage correction factor was used. The PCa-to-urethra distance was recorded as follows: 0 mm (PCa in contact with the urethral mucosa), 0.1- To enable statistical analysis, the Bx core locations were grouped in eight major categories: base (including RB and LB), base/medial base (including RB, LB, RMB and LMB), medial base/medial apex/medial mid/transition zone (including RMB, LMB, RMA, LMA, RMM, LMM, RTZ, LTZ and LPU), lateral base (including RLB and LLB), mid (including RM, LM), lateral mid (including RLM and LLM), apex (including RA and LA) and lateral apex (including RLA and LLA).
The PCa-to-urethra distance subdivided into two (p3 and 43 mm) and all seven categories (0; 0.1-1; 1.1-2; 2.1-3; 3.1-4; 4.1-5; 45 mm) was correlated with iPSA and Bx parameters. The distance categories were arbitrarily chosen, as the precise amount of tissue spared from cryo-injury is not known, but it is believed to be 1-2 mm in most patients. The univariate relationships between the iPSA, Bx parameters and PCa-tourethra distance were examined. Multivariate analyses were performed using multiple logistic regression for the distance subdivided into two categories and multiple linear regression using the seven distance categories as a continuous variable. Variable selection was done using backward elimination and forward selection (n ¼ 234). Interactions between significant predictors were investigated. A P-value of 0.05 or less was considered statistically significant. Statistical analyses were performed with JMP 10 (SAS, Cary, NC, USA).
RESULTS
Patients' median age and iPSA were 59 years and 5.28 ng ml À 1 , respectively. The median number of Bx cores taken was 12 (range 7-37); the median number of cores involved by PCa was 3 (range 1-24). PCa was unilateral in 171 (64%) biopsies and bilateral in 96 (36%). BxGS was 6 in 103 (39%), 7 in 127 (47%), 8 in 30 (11%) and 9 in 7 (3%) cases. The highest percentage of PCa/cores ranged from 5 to 100%. Perineural invasion was found in 68 (25%) biopsies (Table 1 ). The distribution of the PCa location on needle biopsies is summarized in Table 2 .
The mean PCa volume at RP was 272 mm 2 (median 192.5 mm 2 ), ranging from 2 to 2000 mm 2 ; 19% of cases had low volume (o65 mm 2 B o0.5 ml), 44% medium (65-250 mm 2 B 0.5-2.0 ml) and 37% extensive volume (4250 mm 2 B 42.0 ml). PCa-tourethra distance was 0 in 6 (2%), 0.1-1.0 mm in 25 (9.5%), 1.1-2.0 mm in 48 (18%), 2.1-3.0 mm in 48 (18%), 3.1-4.0 mm in 24 (9%), 4.1-5.0 mm in 12 (4.5%) and 45.0 mm in 104 (39%) cases (Figure 1) . PCa-to-urethra distance was p3 mm in 127 (48%) and 43 mm in 140 (52%) cases. The univariate associations between Cancer-to-urethra distance the iPSA and the Bx variables with the PCa-to-urethra distance are summarized in Table 3 . Shorter PCa-to-urethra distance was significantly associated with all aforementioned parameters when subdivided in either 7 or 2 (p3.0 and 43.0 mm) categories. In multivariate analysis of both the two-and the sevencategories of PCa-to-urethra distance the best models included iPSA, highest percentage of Bx PCa and PCa detected at the apex. None of their interactions were significant. The models appear in Table 4 . A nomogram for the model with two categories is displayed in Figure 2 .
DISCUSSION
Focal therapy use has increased significantly over time as a minimally invasive viable treatment option for PCa, particularly in patients with early stage disease who are not candidates for prostatectomy. To date, a number of different ablative modalities have been applied for focal therapy of the prostate gland. 19 Of all the ablative techniques available, cryoablation is the one that has been used and studied for the longest. Although the initial use of cryotherapy in PCa focused on destruction of the whole prostate gland, more recently cryotherapy has been investigated as a tool for focal therapy. 20 Patients undergoing cryoablation for PCa may have a portion of their neoplasm inadequately treated due to urethra-sparing methods in the attempt to avoid urethra injury-related morbidity. However, how much tissue around the urethral warming catheter is spared from the cryo-effect is not exactly known, being that the amount of protected tissue varies with the temperature used in the warming catheter and its dwell time. 21, 22 Data on microwave thermoablation reported by Larson et al. 23 revealed that the mean temperature during treatment climbed rapidly with radial distance from the urethra to a maximum of 54 1C at a distance of B5 mm radially from the urethra. As patients with PCa located in close proximity (o3 mm) to the urethra will probably not benefit from cryoablation, studies have been performed trying to find predictors of PCa-to-urethra distance. 21, 24 In a study of 24 RP specimens performed between 2000 and 2003, Bostwick et al. 25 reported PCa-to-urethra distance to range from 0 to 12 mm; PCa was in contact with the urethra in 12.5% and within 5 mm of the urethra in 46% of cases. In a study of 350 whole-mount RP specimens collected between 1991 and 1993, Leibovich et al. 24 reported that 84% of cases had a focus of cancer within 5 mm of the urethra, and cancer touched the urethra in 17% of the specimens. Rukstalis et al. 21 evaluated 112 whole-mount RP specimens from patients treated from 1998 to 2000 and found 66% of tumors located within 5 mm of the urethra and 45% within 1 mm of the urethra; they did not report the percentage of cases at the urethra.
Similar to Rukstalis et al., 21 61% of the contemporary RP specimens included in our study had cancer within 5 mm of the urethra; PCa was in contact with the urethral mucosa in only 2% of our cases, much less frequently than the 12.5 and 17% recorded in previous studies. 24, 25 The discrepancy between our and other investigators' findings may partially be due to the size of the tumors; only 37% of the cases in our study had a tumor volume 42.0 ml in contrast with 54% of the cases included in the study by Bostwick et al. 25 Similar to our study, Rukstalis et al. 21 reported a median volume of 1.6 ml for the index lesion (defined as the largest lesion).
Leibovich et al. 24 found that a decreasing urethra-cancer distance was significantly associated with increasing rates of PCa recurrence and, similarly to our study, with higher iPSA, BxGS and presence of perineural invasion on needle biopsy. Moreover, higher percentage of Gleason grade four or five in the Bx and cancer present in the apex and base of the RP specimen were more likely to have a shorter urethra-cancer distance. 24 Inversely, from our study, the authors found the percentage of PCa in the Bx specimen not to be associated with urethra-cancer distance.
Rukstalis et al. 21 found that patients with iPSA 410 ng ml -1 , apical and transition zone cancers and total PCa volume 42 cm 3 were statistically more likely to have cancer in the periurethral region; on the other hand, clinical stage, BxGS and prostate volume were not predictive of periurethral PCa. The controversial association between urethra-cancer distance and BxGS may be explained by the different distribution of BxGS among distinct studies; in the current study, the median BxGS was seven (GS 6 ¼ 39%; GS 7 ¼ 47%; GS X8 ¼ 14%); in the study by Leibovich et al. 24 it was five-six (GS p6 ¼ 46%; GS 7 ¼ 28%; GSX8 ¼ 9%) and in the study by Rukstalis et al. 21 it was six (range 4-10).
To the best of our knowledge, the present study was the first to date to find a statistically significant correlation between shorter PCa-to-urethra distance and number of positive Bx cores, highest percentage of PCa in positive cores and presence of PCa detected in Bx cores taken from apex, base and base/medial base. Although Leibovich et al. 24 reported that cancer present in the apex and base of the RP specimen were more likely to have a shorter urethra-cancer distance and Rukstalis et al. 21 suggested that patients with apical and transition zone cancers at RP were statistically more likely to have cancer in the periurethral region, Prediction of prostate cancer to urethra distance MM Padilha et al none of the authors correlated PCa location on needle Bx with PCa-to-urethra distance. Our study suggests that patients with high iPSA, bilateral PCa on needle Bx, high number of positive Bx cores, high BxGS, high percentage of PCa/cores, perineural invasion and PCa detected in Bx from apex, base and/or medial base are probably not ideal candidates for cryotherapy, due to the high risk of having PCa in the periurethral region of the prostate. Alternatively, to ensure adequate treatment, such patients might require colder temperatures in the urethral region, thus being at a higher risk of urethra injury-related morbidity. The inclusion of preoperative parameters, such as iPSA, highest percentage of PCa/cores and PCa detected in biopsies from apex, in the nomogram we have developed could assist clinicians in identifying ideal candidates for cryoablation by providing an accurate preoperative estimation of the individual PCa-to-urethra distance.
An important limitation of the present study is its retrospective nature. Further investigations are needed to determine the strongest clinical and pathological preoperative predictors of shorter PCa-to-urethra distance, in order to discriminate which patients would benefit from focal cryotherapy with minimal side effects and low risk of PCa recurrence. The advent of advanced prostatic imaging, such as multi-parametric diffusion-weighted MRI, with transperineal biopsies is likely to help defining optimal characteristics for candidate selection.
The next step would be to internally validate the first PCa-tourethra distance nomogram we have developed in an independent cohort of patients. 
